Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Day: March 26, 2026

Cell_Gene_Therapy

Cell and Gene Therapy Today—March 26, 2026

This week’s Gene and Cell Therapy update highlights regulatory approvals,…

Rare Disease news

Rare Diseases Today—March 26, 2026

This week’s Rare Diseases update highlights regulatory designations, new…

Cardiovascular

Cardiovascular Today—March 26, 2026

This week’s Cardiovascular update highlights regulatory approvals, device…

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: MSD to acquire Terns

Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

ACC 2026 Preview: Key Cardiology Highlights to Watch
Endocrinology Today—March 31, 2026
Obesity Today—March 31, 2026
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Hematology Today—March 30, 2026

Tags

AAV-based gene therapies adaptive design Alzheimer’s psychosis American Academy of Pediatrics American Society of Clinical Oncology cancer care cancer vaccines Chronic myeloid leukemia clinical strategy clinicaltrials competitive advantage CVC datasecurity digital health innovation digital pill drug development EndometrialCancer ESMO Immuno-Oncology Congress 2025 Etiprimal fair pricing Gastroenterology exit strategy Gene and cell therapy in hematology google ventures Health Systems Transformation HeartFlow Immunology strategy manufacturing scale Manufacturing scale-up mental health mucosal immunology NeOnc Technologies Neuron replacement therapy Oncology strategy Pain patient centricity PBS Australia Rare disease market trends Regulatory catalysts RIPTAC platform Simcere SystImmune Tecvayli Transthyretin Amyloid Cardiomyopathy US health crisis VOICE ASSISTANT

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

ACC 2026 Preview: Key Cardiology Highlights to Watch
Endocrinology Today—March 31, 2026
Obesity Today—March 31, 2026
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Hematology Today—March 30, 2026

TAGS

AAV-based gene therapies adaptive design Alzheimer’s psychosis American Academy of Pediatrics American Society of Clinical Oncology cancer care cancer vaccines Chronic myeloid leukemia clinical strategy clinicaltrials competitive advantage CVC datasecurity digital health innovation digital pill drug development EndometrialCancer ESMO Immuno-Oncology Congress 2025 Etiprimal fair pricing Gastroenterology exit strategy Gene and cell therapy in hematology google ventures Health Systems Transformation HeartFlow Immunology strategy manufacturing scale Manufacturing scale-up mental health mucosal immunology NeOnc Technologies Neuron replacement therapy Oncology strategy Pain patient centricity PBS Australia Rare disease market trends Regulatory catalysts RIPTAC platform Simcere SystImmune Tecvayli Transthyretin Amyloid Cardiomyopathy US health crisis VOICE ASSISTANT

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy